Skip to main content
SpringerLink
Log in

Inhibition of Human CYP3A Catalyzed 1′-Hydroxy Midazolam Formation by Ketoconazole, Nifedipine, Erythromycin, Cimetidine, and Nizatidine

  • Note
  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCES

  1. D. R. Nelson, T. Kamataki, D. J. Waxman, F. P. Guengerich, R. W. Estabrook, R. Feyereisin, F. J. Gonzalez, M. J. Coon, I. C. Gunsalus, O. Gotoh, K. Okuda, and D. W. Nebert: The P450 superfamily: Update on new sequences, gene mapping, accession numbers, earily trival names of enzymes, and nomenclature. DNA Cell Biol. 12:1–51 (1993).

    Google Scholar 

  2. S. A. Wrighton and J. C. Stevens: The human hepatic cytochromes P450 involved in drug metabolism. Crit. Rev. Tox. 22:1–21 (1992).

    Google Scholar 

  3. P. K. Honig, D. C. Wortham, K. J. Zamani, D. P. Conner, J. C. Mullin, and L. R. Cantilena: Terfenadine-ketoconazole interaction: Pharmacokinetic and electrocardiographic consequences. JAMA 269:1513–1518 (1993).

    Google Scholar 

  4. P. K. Honig, R. L. Woosley, K. Zamani, D. P. Conner, and L. R. Cantilena: Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin. Pharmacol. Ther. 52:231–238 (1992).

    Google Scholar 

  5. T. A. van der Hoeven and M. J. Coon: Preparation and properties of partially purified cytochrome P-450 and reduced nicotinamide adenine dinucleotide phosphate-cytochrome P-450 reductase from rabbit liver microsomes. J. Biol. Chem. 249:6302–6310 (1974).

    Google Scholar 

  6. T. Kronbach, D. Mathys, M. Umeno, F. J. Gonzalez, and U. A. Meyer: Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Molec. Pharmacol. 36:89–96 (1989).

    Google Scholar 

  7. I. H. Segel: Enzyme kinetics: Behavior and analysis of rapid equilibrium and steady-state enzyme systems, John Wiley and Sons, New York, 1975.

    Google Scholar 

  8. M. P. Gascon and P. Dayer: In vitro forecasting of drugs which may interfere with the biotransformation of midazolam. Eur. J. Clin. Pharmacol. 41:573–578 (1991).

    Google Scholar 

  9. G. T. Tucker: The rational selection of drug interaction studies: Implications of recent advances in drug metabolism. Internat. J. Clin. Pharmacol. Ther. Toxicol. 30:550–553 (1992).

    Google Scholar 

  10. Physicians Desk Reference. 47th edition. Medical Economics Data, a division of Medical Economics Company Inc., Montvale, NJ, 1993.

  11. C. H. Kleinbloesem, P. van Brummelen, and D. D. Breimer: Nifedipine, relationship between pharmacokinetics and pharmacodynamics. Clin. Pharmacokinetics 12:12–29 (1987).

    Google Scholar 

  12. M. Murray: Mechanisms of the inhibition of cytochrome P450-mediated drug oxidation by therapeutic agents. Drug Metab. Rev. 18:55–81 (1987).

    Google Scholar 

  13. A. F. Shinn: Clinical relevance of cimetidine drug interactions. Drug Safety 7:245–267 (1992).

    Google Scholar 

  14. C. C. Peck, R. Temple and J. M. Collins. Understanding consequences of concurrent therapies. JAMA 269:1550–1552 (1993).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Drug Metabolism and Disposition, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Mail Drop 0825, Indianapolis, Indiana, 46285

    Steven A. Wrighton & Barbara J. Ring

Authors
  1. Steven A. Wrighton
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Barbara J. Ring
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wrighton, S.A., Ring, B.J. Inhibition of Human CYP3A Catalyzed 1′-Hydroxy Midazolam Formation by Ketoconazole, Nifedipine, Erythromycin, Cimetidine, and Nizatidine. Pharm Res 11, 921–924 (1994). https://doi.org/10.1023/A:1018906614320

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1018906614320

Search

Navigation